These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 36081276)
1. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Lanteri-Minet M; Ducros A; Francois C; Olewinska E; Nikodem M; Dupont-Benjamin L Cephalalgia; 2022 Dec; 42(14):1543-1564. PubMed ID: 36081276 [TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383 [TBL] [Abstract][Full Text] [Related]
3. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P; J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917 [TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. Boudreau G; Finkelstein I; Graboski C; Ong M; Christie S; Sommer K; Bhogal M; Davidovic G; Becker WJ Can J Neurol Sci; 2022 Jul; 49(4):540-552. PubMed ID: 34218836 [TBL] [Abstract][Full Text] [Related]
5. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924 [TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267 [TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF; Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038 [TBL] [Abstract][Full Text] [Related]
9. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333 [TBL] [Abstract][Full Text] [Related]
10. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. Khalil M; Zafar HW; Quarshie V; Ahmed F J Headache Pain; 2014 Sep; 15(1):54. PubMed ID: 25178393 [TBL] [Abstract][Full Text] [Related]
11. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. Negro A; Curto M; Lionetto L; Martelletti P J Headache Pain; 2015; 17():1. PubMed ID: 26792662 [TBL] [Abstract][Full Text] [Related]
12. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Silberstein SD; Diener HC; Dodick DW; Sommer K; Lipton RB Headache; 2024; 64(7):838-848. PubMed ID: 38982666 [TBL] [Abstract][Full Text] [Related]
13. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713 [TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197 [TBL] [Abstract][Full Text] [Related]
15. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545 [TBL] [Abstract][Full Text] [Related]
16. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Mathew NT; Jaffri SF Headache; 2009; 49(10):1466-78. PubMed ID: 19912346 [TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721 [TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341 [TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235 [TBL] [Abstract][Full Text] [Related]
20. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]